Hebei Senlang Biotechnology Inc., Ltd.

This early-phase trial tests whether a patient's own immune cells, engineered to target BCMA and/or CD19, can calm severe ulcerative colitis that hasn't responded to other treatments. Twelve adults with moderate-to-severe active disease will receive a single infusion of these CAR…

This phase 2 trial tests a new treatment called Senl_B19 CAR-T cells for people aged 3 to 25 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill cancer cel…